Financial Survey: Eton Pharmaceuticals (NASDAQ:ETON) & Cronos Group (NASDAQ:CRON)

Cronos Group (NASDAQ:CRON) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent recommendations for Cronos Group and Eton Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	0	2	3	0	2.60
Eton Pharmaceuticals	0	1	4	1	3.00

Cronos Group presently has a consensus price target of $2.30, indicating a potential downside of 27.22%. Eton Pharmaceuticals has a consensus price target of $67.50, indicating a potential upside of 27.65%. Given Eton Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Eton Pharmaceuticals is more favorable than Cronos Group.

Insider and Institutional Ownership

8.7% of Cronos Group shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 7.8% of Cronos Group shares are held by insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Cronos Group and Eton Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	$179.09 million	6.50	-$9.45 million	$0.20	15.80
Eton Pharmaceuticals	$105.59 million	14.31	-$4.60 million	$0.38	139.16

Eton Pharmaceuticals has lower revenue, but higher earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Cronos Group has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Comparatively, Eton Pharmaceuticals has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500.

Profitability

This table compares Cronos Group and Eton Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cronos Group	39.08%	4.85%	4.62%
Eton Pharmaceuticals	12.02%	40.13%	12.37%

Summary

Eton Pharmaceuticals beats Cronos Group on 12 of the 14 factors compared between the two stocks.

About Cronos Group

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.